PROMIS

ProMIS Neurosciences is a clinical-stage biotechnology company developing selective therapeutics against toxic misfolded proteins implicated in neurodegenerative diseases. Its lead asset, PMN310, is a monoclonal antibody in Phase 1b development for Alzheimer's disease that is designed to selectively bind toxic amyloid-beta oligomers while sparing plaques and monomers. The company is also advancing preclinical programs against misfolded TDP-43 for ALS/FTD and alpha-synuclein for Parkinson's disease and related synucleinopathies, alongside vaccine approaches. ProMIS differentiates itself through its proprietary EpiSelect platform, which uses computational modeling to identify disease-specific epitopes on misfolded proteins. The company is publicly traded on Nasdaq and operates from Toronto and Cambridge, Massachusetts.